Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Genevieve Boland

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Cell|July 19, 2018
Toward Minimal Residual Disease-Directed Therapy in MelanomaFlorian Rambow, Aljosja Rogiers, Oskar Marin-Bejar, et al.
Medrxiv : the Preprint Server for Health Sciences|January 30, 2023
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort studyShijia Zhang, Kimberly Tang, Guihong Wan, et al.
Journal of the American Academy of Dermatology|February 3, 2023
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort studyShijia Zhang, Kimberly Tang, Guihong Wan, et al.
Biorxiv : the Preprint Server for Biology|October 10, 2024
A unique interplay of access and selection shapes peritoneal metastasis evolution in colorectal cancerEmma Ce Wassenaar, Alexander N Gorelick, Wei-Ting Hung, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
Distinct malignant cell states and myeloid glutamate signaling associated with aggressive pancreatic neuroendocrine tumorsJeanna M Arbesfeld-Qiu, Jae-Won Cho, Phuong T T Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2026
Distinct malignant cell states and myeloid glutamate signaling associated with aggressive pancreatic neuroendocrine tumorsJeanna M Arbesfeld-Qiu, Jae-Won Cho, Phuong T T Nguyen, et al.
Cancer Discovery|December 20, 2018
ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant MelanomaRani Ojha, Nektaria M Leli, Angelique Onorati, et al.
EMBO Molecular Medicine|April 14, 2018
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanomaIleabett M Echevarría-Vargas, Patricia I Reyes-Uribe, Adam N Guterres, et al.
Molecular Systems Biology|March 13, 2019
Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapyAvinash Das Sahu, Joo S Lee, Zhiyong Wang, et al.
Journal of the American Academy of Dermatology|February 24, 2023
Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapyNga Nguyen, Guihong Wan, Pearl Ugwu-Dike, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Cell|July 19, 2018
Toward Minimal Residual Disease-Directed Therapy in MelanomaFlorian Rambow, Aljosja Rogiers, Oskar Marin-Bejar, et al.
Medrxiv : the Preprint Server for Health Sciences|January 30, 2023
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort studyShijia Zhang, Kimberly Tang, Guihong Wan, et al.
Journal of the American Academy of Dermatology|February 3, 2023
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort studyShijia Zhang, Kimberly Tang, Guihong Wan, et al.
Biorxiv : the Preprint Server for Biology|October 10, 2024
A unique interplay of access and selection shapes peritoneal metastasis evolution in colorectal cancerEmma Ce Wassenaar, Alexander N Gorelick, Wei-Ting Hung, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
Distinct malignant cell states and myeloid glutamate signaling associated with aggressive pancreatic neuroendocrine tumorsJeanna M Arbesfeld-Qiu, Jae-Won Cho, Phuong T T Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2026
Distinct malignant cell states and myeloid glutamate signaling associated with aggressive pancreatic neuroendocrine tumorsJeanna M Arbesfeld-Qiu, Jae-Won Cho, Phuong T T Nguyen, et al.
Cancer Discovery|December 20, 2018
ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant MelanomaRani Ojha, Nektaria M Leli, Angelique Onorati, et al.
EMBO Molecular Medicine|April 14, 2018
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanomaIleabett M Echevarría-Vargas, Patricia I Reyes-Uribe, Adam N Guterres, et al.
Molecular Systems Biology|March 13, 2019
Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapyAvinash Das Sahu, Joo S Lee, Zhiyong Wang, et al.
Journal of the American Academy of Dermatology|February 24, 2023
Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapyNga Nguyen, Guihong Wan, Pearl Ugwu-Dike, et al.
Pageof 5